Quest Diagnostics DGX is set to release its first-quarter 2025 results on April 22, before the market opens. The renowned diagnostics provider posted adjusted earnings per share (EPS) of $2.23 in the ...

The market expects Quest Diagnostics (DGX) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended March 2025. This widely-known consensus ...

BofA analyst Michael Ryskin raised the firm’s price target on Quest Diagnostics (DGX) to $198 from $190 and keeps a Buy rating on the shares.

Shares of Quest Diagnostics Inc. DGX slid 2.74% to $159.80 Tuesday, on what proved to be an all-around dismal trading session ...

Quest Diagnostics (NYSE:DGX) recently introduced the AD-Detect™ blood test, a significant development aimed at confirming Alzheimer's-related amyloid brain pathology. Over the last quarter, the ...

Last offseason, the Carolina Panthers were forced to send edge rusher Brian Burns to the New York Giants in a sign-and-trade, ...

The most recent lawsuit is from winter 2024, when the California attorney general announced a $5 million settlement with ...

Quest Diagnostics Inc. closed 8.28% below its 52-week high of $178.87, which the company reached on March 10th.

Investment analysts at Leerink Partnrs dropped their Q2 2025 earnings per share (EPS) estimates for shares of Quest ...

Fintel reports that on April 2, 2025, Redburn Atlantic initiated coverage of Quest Diagnostics (NYSE:DGX) with a Buy ...

Barclays analyst Luke Sergott maintained a Hold rating on Quest Diagnostics (DGX – Research Report) today and set a price target of $175.00.

"Quest's AD-Detect suite of advanced diagnostics has grown to include a range of validated blood-based biomarkers, giving providers options for personalizing testing for the individual patient ...